Skip to main content
. 2020 Mar 7;2020:baaa012. doi: 10.1093/database/baaa012

Figure 4. The workflow shows the process of application of CancerLivER in the prioritisation of GPC3 as a diagnostic biomarker and as a drug target for HCC.

Figure 4